Balchem Corporation (BCPC)

Currency in USD
174.01
+3.21(+1.88%)
Closed·
174.010.00(0.00%)
·
Earnings results expected in 8 days
BCPC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
171.79176.35
52 wk Range
139.17177.40
Key Statistics
Prev. Close
170.8
Open
171.79
Day's Range
171.79-176.35
52 wk Range
139.17-177.4
Volume
109.71K
Average Volume (3m)
175.8K
1-Year Change
5.6206%
Book Value / Share
39.99
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BCPC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
191.00
Upside
+9.76%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Balchem Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Balchem Corporation Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

Industry
Chemicals
Employees
1355

Balchem Corporation Earnings Call Summary for Q2/2025

  • Record Q2 2025 revenue of $255M, up 9.1% YoY; net income rose 19.4% to $38M; adjusted EBITDA up 11.2% to $69M
  • Strategic expansion in microencapsulation capacity; new product launches in nutrition segments drive growth
  • Stock closed at $143.11, down 0.55% post-earnings; trading near 52-week low with P/E ratio of 76.63
  • FY2025 revenue forecast at $5.161B, FY2026 at $5.399B; double-digit growth expected in microencapsulation business
  • European tariffs on Chinese choline pose challenge; company plans to offset 50% through supply chain adjustments
Last Updated: 2025-10-14, 06:36 p/m
Read Full Transcript

Compare BCPC to Peers and Sector

Metrics to compare
BCPC
Peers
Sector
Relationship
P/E Ratio
37.8x31.7x1.9x
PEG Ratio
1.67−0.410.00
Price/Book
4.3x2.2x1.6x
Price / LTM Sales
5.6x1.6x1.4x
Upside (Analyst Target)
10.2%0.0%17.0%
Fair Value Upside
Unlock1.3%−2.1%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 191.00
(+9.76% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Rothschild Redburn
Hold162.00-6.90%-New CoverageDec 05, 2025
H.C. Wainwright
Buy189.00+8.61%180.00MaintainAug 05, 2025
H.C. Wainwright
Buy180.00+3.44%190.00MaintainApr 28, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.57%
Dividend Yield
0.55%
Industry Median 2.55%
Annualized payout
0.96
Paid unevenly
5-Years Growth
+10.84%
Growth Streak

Earnings

Latest Release
Oct 21, 2025
EPS / Forecast
1.24 / 1.15
Revenue / Forecast
267.56M / 258.28M
EPS Revisions
Last 90 days

BCPC Income Statement

People Also Watch

100.25
IPAR
+2.42%
505.46
CVCO
+4.73%
105.64
ADUS
-1.18%
49.08
CRVL
-4.85%
32.46
EXLS
+0.37%

FAQ

What Is the Balchem (BCPC) Stock Price Today?

The Balchem stock price today is 174.01

What Stock Exchange Does Balchem Trade On?

Balchem is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Balchem?

The stock symbol for Balchem is "BCPC."

Does Balchem Pay Dividends? What’s The Current Dividend Yield?

The Balchem dividend yield is 0.55%.

What Is the Balchem Market Cap?

As of today, Balchem market cap is 5.65B.

What Is Balchem's Earnings Per Share (TTM)?

The Balchem EPS (TTM) is 4.57.

When Is the Next Balchem Earnings Date?

Balchem will release its next earnings report on Feb 13, 2026.

From a Technical Analysis Perspective, Is BCPC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Balchem Stock Split?

Balchem has split 8 times.

How Many Employees Does Balchem Have?

Balchem has 1355 employees.

What is the current trading status of Balchem (BCPC)?

As of Feb 05, 2026, Balchem (BCPC) is trading at a price of 174.01, with a previous close of 170.80. The stock has fluctuated within a day range of 171.79 to 176.35, while its 52-week range spans from 139.17 to 177.40.

What Is Balchem (BCPC) Price Target According to Analysts?

The average 12-month price target for Balchem is USD191.00, with a high estimate of USD220 and a low estimate of USD162. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +9.76% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.